Repligen Corporation ($RGEN) Stock Forecast: Down 5.3% Today

What is Repligen Corporation?

Repligen Corporation (RGEN) is a bioprocessing technology company that focuses on the development and commercialization of high-value products used in the process of manufacturing biological drugs.

Why is Repligen Corporation going down?

RGEN stock is down 5.3% on Nov 14, 2024 17:53

• Repligen (RGEN) reported strong Q3 earnings and revenue beats, showcasing a robust financial performance.
• Despite the positive earnings report, the stock experienced a bearish movement, possibly due to the company lowering its guidance for 2024 total sales.
• Investors might be reacting to the mixed guidance provided by Repligen, causing a sell-off in the stock despite the positive earnings surprises.
• The market movement could also be influenced by profit-taking activities following the stock's recent strong performance, as investors reassess their positions based on the new sales outlook provided by the company.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Company News for Nov 13, 2024

Companies In The News Are: MOS, RGEN, SE, FOUR.

https://www.zacks.com/stock/news/2369374/company-news-for-nov-13-2024

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.

https://www.zacks.com/stock/news/2369173/repligen-beats-on-q3-earnings-sales-narrows-24-sales-view

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth - Repligen ( NASDAQ:RGEN )

Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the consensus of $153.23 million.

https://www.benzinga.com/general/health-care/24/11/41914004/repligen-q3-earnings-beat-expectations-highlights-improving-market-conditions-analyst-says-we

Repligen ( RGEN ) Q3 Earnings and Revenues Beat Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 26.47% and 1.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2368715/repligen-rgen-q3-earnings-and-revenues-beat-estimates

Trending Today

Optimism ($OP) Crypto Forecast: Down 5.4% Today

dogwifhat ($WIF) Crypto Forecast: Down 7.8% Today

XRP ($XRP) Crypto Forecast: Up 20.5% Today

Bonk ($BONK) Crypto Forecast: Up 6.6% Today

Litecoin ($LTC) Crypto Forecast: Up 9.9% Today

Pepe ($PEPE) Crypto Forecast: Up 20.0% Today

Advance Auto Parts Inc W/I ($AAP) Stock Forecast: Down 7.6% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Down 5.5% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.4% Today

Cronos Group Inc. ($CRON) Stock Forecast: Down 6.1% Today

Repligen Corporation Price History

26.08.2024 - RGEN Stock was up 5.9%

• Repligen announced the grand opening of its Repligen Training & Innovation Center (RTIC) at its Waltham headquarters, showcasing a commitment to enhancing customer experience and innovation.
• The move to support biopharma and CDMO customer experience with the company's bioprocessing technologies likely generated positive investor sentiment, leading to the bullish movement in RGEN stock.
• The focus on training and innovation could signal potential growth opportunities and increased competitiveness in the bioprocessing technology sector, driving optimism among investors and contributing to the stock's upward momentum.

16.07.2024 - RGEN Stock was down 10.9%

• There was a notable bearish movement in Repligen Corp. (RGEN), likely attributed to profit-taking post recent gains.
• Maravai Lifesciences Holdings Inc. observed a rise in its shares amid speculations of a potential acquisition offer from Repligen Corp., which may have diverted investor attention from Repligen towards Maravai, affecting Repligen's stock negatively.
• The uncertainty surrounding the potential acceptance of the acquisition offer could have heightened volatility in Repligen's stock, contributing to the bearish trend.
• Comments in an investor letter from Conestoga Capital Advisors regarding a moderation in economic indicators and equity markets might have prompted a more cautious stance towards Repligen Corp., influencing the bearish movement.

16.07.2024 - RGEN Stock was down 5.4%

• Second-quarter investor communication emphasized a period of market moderation.
• Economic signals pointed to decelerating growth and decreasing inflation, likely influencing investor confidence.
• The trend of moderation in stock markets could have influenced the negative movement in RGEN shares.
• Investors might be reassessing Repligen Corp.'s growth potential in light of prevailing market circumstances.

03.08.2024 - RGEN Stock was down 5.2%

• Following the latest earnings disclosure, Repligen's stock experienced a 13.1% drop.
• Concerns around the company's future earnings prospects may have fueled the bearish movement.
• The absence of positive forecasts or updates on forthcoming initiatives might have impacted RGEN's stock performance adversely.
• Market participants appear to be awaiting clearer indications of a possible recovery before contemplating investments in Repligen.

14.10.2024 - RGEN Stock was down 5.3%

• Repligen (RGEN) reported strong Q3 earnings and revenue beats, showcasing a robust financial performance.
• Despite the positive earnings report, the stock experienced a bearish movement, possibly due to the company lowering its guidance for 2024 total sales.
• Investors might be reacting to the mixed guidance provided by Repligen, causing a sell-off in the stock despite the positive earnings surprises.
• The market movement could also be influenced by profit-taking activities following the stock's recent strong performance, as investors reassess their positions based on the new sales outlook provided by the company.

23.09.2024 - RGEN Stock was down 5.5%

• The negative market movement could be linked to concerns about Repligen's upcoming Q3 earnings release, amid worries of potential underperformance.
• Investors possibly reacted to perceived limited growth opportunities in the earnings report, resulting in a sell-off of RGEN shares.
• Uncertainty surrounding the company's ability to meet earnings projections may have influenced the downward trend in stock price today.

12.10.2024 - RGEN Stock was up 7.7%

• Repligen (RGEN) reported Q3 earnings and revenues that surpassed analysts' estimates, indicating strong financial performance.
• The better-than-expected results suggest that the company's bioprocessing technologies are in high demand, potentially leading to increased market share and profitability.
• Investors may be reacting positively to the earnings beat, driving the bullish movement in RGEN's stock price today.
• The outperformance in earnings and revenues could signal continued growth and success for Repligen, attracting more investors to the stock.

12.10.2024 - RGEN Stock was up 6.2%

• Repligen (RGEN) saw a notable upward trend today subsequent to its Q3 earnings announcement.
• The company's reported adjusted EPS and sales exceeded expectations, showcasing robust financial performance and growth potential.
• Analysts express optimism regarding Repligen's future growth prospects, attributing this to enhanced market conditions and the company's strong competitive position.
• The favorable earnings and revenue outcomes likely bolstered investor confidence in Repligen, propelling the stock price upwards.

30.06.2024 - RGEN Stock was up 12.2%

• Positive financial results were reported for the second quarter of 2024, showcasing strong performance and growth in Repligen's bioprocessing technology sector.
• The announcement of the acquisition of Chromatography Innovator Tantti indicates strategic expansion and enhancement of Repligen's capabilities, likely boosting investor confidence in the company's future prospects.
• The positive news surrounding Repligen's financials and strategic acquisitions could have led to increased investor interest and buying activity, driving the bullish movement in the stock price today.

30.06.2024 - RGEN Stock was up 10.0%

• The bullish movement in RGEN's stock today could be attributed to the following factors:
• Despite a slight miss in revenue estimates and a decrease in adjusted gross margin, the company's earnings were in line with expectations, indicating consistent performance.
• Investors show optimism about the company's future prospects as seen in the financial results for the second quarter of 2024.
• The market's positive reaction may stem from the company's ability to sustain earnings and revenue consistency, despite challenges like China weakness and missing estimates in some financial metrics.

06.07.2024 - RGEN Stock was up 6.6%

• The executive selling over $1.1 million in company stock might have initially raised concerns among investors, but this was overshadowed by the company's second-quarter earnings meeting estimates.
• Despite narrowing revenue guidance for 2024 due to China headwinds, the fact that earnings and revenues matched estimates reassured investors.
• Analysts revising their forecasts following Q2 results could have contributed positively to the bullish movement, indicating confidence in the company's performance.
• Overall, the market seems to have focused more on the company's solid financial results and analyst confidence rather than the slight guidance adjustment.

02.07.2024 - RGEN Stock was down 5.0%

• The company's second-quarter earnings were in line with expectations, with sales almost reaching estimates and adjusted EPS aligning with consensus.
• Repligen adjusted its revenue guidance for 2024, citing challenges in China that affected investor confidence.
• Despite meeting financial expectations, the stock price declined as analysts adjusted their forecasts and expressed concerns about the China market.
• The stock's bearish movement was partly influenced by a slight revenue miss and a decrease in EPS during the second quarter.